GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Capex-to-Revenue

Lyka Labs (BOM:500259) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Lyka Labs's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹277.67 Mil.

Hence, Lyka Labs's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


Lyka Labs Capex-to-Revenue Historical Data

The historical data trend for Lyka Labs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Capex-to-Revenue Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.04 0.09 0.08

Lyka Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lyka Labs's Capex-to-Revenue

For the Biotechnology subindustry, Lyka Labs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Capex-to-Revenue falls into.



Lyka Labs Capex-to-Revenue Calculation

Lyka Labs's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-92.314) / 1111.946
=0.08

Lyka Labs's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 277.673
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyka Labs  (BOM:500259) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Lyka Labs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines